Vaccines Improve Public Opinion Of Pharma, Despite Cost Worries With Chart: Public Holds Favorable Views of Big Pharma, But Still Wants Drug Pricing Reforms

In recent years, the pharmaceutical industry has not been popular with the public: Problems like the rising cost of prescription drugs and the opioid epidemic combined to make the industry the least popular nationwide in a 2019 Gallup poll. According to a recent poll, the public now thinks better of the industry due to the rapid development of COVID-19 vaccines — but still wants drug prices to be reined in.

In a March 2021 national survey, progressive polling group Data for Progress found that 56% of respondents had a favorable view of pharmaceutical companies (see infographic, p. 6). Vaccine developers scored well on an individual basis: majorities had favorable views of Johnson & Johnson (68%), Moderna, Inc. (60%) and Pfizer Inc. (65%). Also, 75% of respondents said they approve of those specific companies’ vaccine development efforts. However, the poll also found that 73% of respondents disapprove of “how pharmaceutical companies are handling the rising cost of prescription drugs.”

© 2024 MMIT
Peter Johnson

Peter Johnson

Peter has worked as a journalist since 2011 and has covered health care since 2020. At AIS Health, Peter covers trends in finance, business and policy that affect the health insurance and pharma sectors. For Health Plan Weekly, he covers all aspects of the U.S. health insurance sector, including employer-sponsored insurance, Medicaid managed care, Medicare Advantage and the Affordable Care Act individual marketplaces. In Radar on Drug Benefits, Peter covers the operations of (and conflicts between) pharmacy benefit managers and pharmaceutical manufacturers, with a particular focus on pricing dynamics and market access. Before joining AIS Health, Peter covered transportation, public safety and local government for various outlets in Seattle, his hometown and current place of residence. He graduated with a B.A. from Colby College.

Related Posts

businessman-viewing-news-update-journalism-headline-on-a-laptop
June 13

News Briefs: State Officials Urge SCOTUS Review of PBM Regulation Case

READ MORE
scientist-in-lab
June 13

Midsize Plans Struggle to Pay for Cell, Gene Therapies, Execs Say

READ MORE
injector-pen
June 13

Medicaid Programs Are Slow to Cover GLP-1s, but That Could Soon Change

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today